A Phase I Study to Assess Safety and Tolerability of a Live Biotherapeutic Product (SVT-1B149) in the treatment of Chronic Functional Constipation in Adult Participants
Latest Information Update: 21 Oct 2021
At a glance
- Drugs SVT-1B149 (Primary)
- Indications Constipation; Irritable bowel syndrome
- Focus Adverse reactions
- Sponsors Servatus Biopharmaceuticals
- 15 Oct 2021 Recruitment completion is expected on 29/07/2022 according to Australian New Zealand Clinical Trials Registry.
- 15 Oct 2021 Accrual to date is 22 participants as per Australian New Zealand Clinical Trials Registry record.
- 15 Oct 2021 Planned End Date changed from 31 Dec 2021 to 31 Oct 2022.